New clinical study - Novaliq NovaTears®+Omega-3 eye drops
GENERAL
Thu, Jul 29 2021 08:56 am
NovaTears®+Omega-3, an innovative dry eye treatment in-licensed and distributed in Australia and New Zealand by AFT Pharmaceuticals, is a significantly effective treatment for evaporative Dry Eye Disease (DED), a new clinical study1 has found.
Please see the attached announcement for more information.
Announcement PDF
Markets News
Markets
Fletcher dodges product recall in upbeat end to August for NZX 50
The S&P/NZX 50 Index rose 97.07 points, or 0.8%, to 12,447.68.
Markets
Fletcher Building expects $168m hit from leaky pipes response
Fletcher Building subsidiary Iplex Australia to cover 80% of repair costs.
Markets
Ritchies posts $17m annual net loss
The bus operator's net loss widened from $8m to $17m in the year to March 31.
